- TRex Bio is marketing 8.3 million shares at $14 to $16 to raise as much as $133.3 million, valuing the early-stage autoimmune and inflammatory disease company at about $439 million at the top of the range. Pricing is expected October 8 and the shares are to trade on the Nasdaq Global Select Market under TRXB.
- The cap table is unusual for its concentration of strategic investors. Eli Lilly, Pfizer Ventures, Johnson and Johnson Innovation, SV Health Investors, Janus Henderson, Alexandria Venture Investments, Delos Capital and Polaris Partners are all shareholders. Eli Lilly has indicated interest in buying shares in the offering while stating its stake will not exceed 19.9%.
- Proceeds will advance TRB-061, the lead candidate, which is in early-stage trials in patients with moderate-to-severe atopic dermatitis, with topline data expected in the middle of next year. A second candidate, TRB-071 for inflammatory bowel disease, is due to enter a Phase 1 trial in the first half of 2027.
- Losses are widening as trials progress, with a net loss of $34.8 million in 2025 against $3.1 million the prior year. The listing follows a strong year for the sector, with biotech and pharmaceutical IPOs raising $7.6 billion, nearly six times the same period last year.
What Happened?
Chief executive Johnston Erwin spent 36 years at Eli Lilly before joining the company, where he led Lilly New Ventures, the drugmaker internal venture capital arm. TRex raised $50 million in January through an additional closing of Series B preferred stock that brought in Janus Henderson and Balyasny Asset Management.
Why It Matters?
The 19.9% figure is not arbitrary and it tells you how Eli Lilly views this asset. Crossing 20% ownership generally triggers equity-method accounting and raises questions about significant influence and control, so capping just beneath it allows Lilly to take the largest position available without those consequences. Combined with a chief executive who spent 36 years at Lilly and ran its venture arm, this looks like a strategic option on a programme rather than a passive financial holding, and public investors are buying alongside a party with far better information about the science. Having Pfizer and Johnson and Johnson on the same register reinforces that the asset has been examined closely by people who would know. That is genuine validation and it is also a concentration of influence worth understanding. The valuation is a single binary. At $439 million the company has two assets, one in early-stage trials with topline data roughly a year away and one not entering Phase 1 until 2027, so essentially the entire value rests on the TRB-061 readout in mid-2027. Atopic dermatitis is a large indication with established biologic competitors, which means the data must show differentiation rather than merely efficacy. Investors should size the position as what it is, which is a bet on one dataset. The sector backdrop deserves a note of caution too. Biotech listings raising nearly six times last year amount signals a wide-open window, and companies list when they can rather than when they must. Windows close, and the quality distribution of what gets listed tends to widen as they do.
What Next?
Pricing on October 8 is the immediate event, and where it lands within the $14 to $16 range indicates institutional appetite. Watch whether Eli Lilly actually takes shares in the offering and how close it goes to the 19.9% ceiling, since that is the clearest signal of strategic intent. Topline data for TRB-061 in the middle of next year is the event that determines the outcome for this company, and nothing between now and then changes the underlying question. The TRB-071 Phase 1 start in the first half of 2027 provides a second shot but on a far longer timeline. For the sector, whether the $7.6 billion IPO pace continues into next year will show if the window remains open for companies at this stage of development.
Affected Tickers and Coins: TRXB, LLY, JNJ, PFE, JHG, ARE
Source: Bloomberg
